Skip to main content
. 2022 Dec 15;122(5):384–392. doi: 10.1016/j.jfma.2022.12.002

Table 1.

Anti-SARS-CoV-2 spike IgG (BAU/mL) titers at 14- and 28-days post second vaccine dose, geometric means (95%CI), n = 399.

14 days p-value 28 days p-value
Gender Male (n = 101) 1736.9 (1344.9–2243.0) 0.301 1192.3 (943.5–1506.7) 0.189
Female (n = 298) 1474.7 (1257.3–1729.6) 989.3 (858.0–1140.6)
Local erythema Yes (n = 23) 3575.0 (2713.8–4709.5) <0.001∗ 2126.1 (1624.7–2782.2) <0.001∗
No (n = 376) 1459.7 (1267.8–1680.7) 992.6 (874.5–1126.6)
Local swelling Yes (n = 41) 3256.6 (2591.7–4092.0) <0.001∗ 1939.8 (1557.2–2416.3) <0.001∗
No (n = 358) 1410.4 (1218.8–1632.1) 967.2 (848.4–1102.6)
Local Pain Yes (n = 326) 1889.5 (1647.9–2166.5) <0.001∗ 1236.7 (1092.7–1399.7) <0.001∗
No (n = 74) 611.4 (430.5–868.1) 474.0 (345.9–649.6)
Fever ≥ 38 °C Yes (n = 136) 2894.0 (2479.5–3377.6) <0.001∗ 1791.0 (1552.9–2065.7) <0.001∗
No (n = 263) 1108.1 (928.4–1322.6) 781.2 (666.4–915.8)
Arthralgia/arthritis Yes (n = 31) 3236.4 (2621.5–3995.5) <0.001∗ 1920.1 (1578.2–2336.2) <0.001∗
No (n = 368) 1443.6 (1250.2–1666.9) 984.7 (865.2–1120.7)
Nausea/vomit Yes (n = 22) 2652.3 (1588.9–4427.5) 0.055 1599.8 (1003.1–2551.6) 0.090
No (n = 377) 1488.9 (1294.7–1712.2) 1011.3 (891.9–1146.6)
Chills Yes (n = 158) 2466.8 (2084.5–2919.1) <0.001∗ 1544.4 (1326.3–1798.4) <0.001∗
No (n = 241) 1127.2 (936.5–1356.8) 800.3 (677.1–945.9)
Headache Yes (n = 179) 1899.0 (1594.8–2261.2) 0.004∗ 1213.7 (1039.7–1416.9) 0.019∗
No (n = 220) 1294.1 (1061.4–1577.7) 913.4 (763.1–1093.4)
Myalgia Yes (n = 292) 2067.9 (1803.2–2371.4) <0.001∗ 1347.8 (1191.3–1524.9) <0.001∗
No (n = 107) 684.1 (511.5–914.8) 508.8 (391.8–660.7)
Fatigue Yes (n = 299) 1885.6 (1633.1–2177.1) <0.001∗ 1242.4 (1091.4–1414.2) <0.001∗
No (n = 100) 834.3 (618.2–1125.8) 605.9 (463.4–792.1)
Systemic Rash Yes (n = 30) 1786.4 (1065.8–2994.2) 0.534 1113.1 (712.4–1739.2) 0.745
No (n = 369) 1518.4 (1319.1–1747.7) 1031.3 (908.5–1170.7)

IgG: immunoglobulin G, BAU/mL: binding antibody units/mL, CI: confidence interval.